tracer solutes, 137 -tained in the alveolar space by lung epithelial sieving, but absorbed at the same rate of water. Rapid absorption of alveolar liquid was not associated with its retention in the lung. Wet/dry ratio was 4.3+0.3 at 1 hour and 4.5+0.3 after 2 hours. At 4 hours it was signifTcantly greater, 5.55074. Positive pressure ventilation of immature lambs produces a much more rapid initial absorp tion of fetal alveolar liquid than previously measured in spontaneously breathing mature lambs, > 90% in the 1st hour vs 25%. Molecular sieving of alveolar liquid solutes typical of term fetuses was absent. The expected accumulation of excess lung water in immature lungs occurred only after completion of clearance of fetal alveolar liquid from the lungs. The edema of immature lungs is not retention of fetal alveolar liquid in the lung but a later phenomenon and of defferent origin. (Supported by Grant HL22552). 
EFFECTIVENESS OF VITAMIN E (E) ADMINISTRATION
The increasing use of phototherapy for the treatment of neonatal jaundice has generated some concern in view of the potential long-term genetic consequences of this therapeutic modality. Our laboratory has determined that light at wavelengths 1 4 5 0 nm is the portion of the visible spectrum responsible for the in vitro and in vivo DNA-modifying activity of phototherapy. In view of this and subsequent work which has shown that light at wavelengths > 460 nm generate water-soluble bilirubin photoisomers, we have developed a new, portable phototherapy unit in which more than 95% of the spectral emission falls between 460 and 480 nm. The light source is a 5 kilowatt mercury arc lamp which has been doped with metal halides. The light is then passed through a series of three filters which remove all undesired radiation, including infrared. The resulting irradiance is 20 watts/~' over an area 60 x 45 cm, or 10 times the 460-480 nm spectral output of a standard phototherapy unit (Duro Test, Vita Lite). Using UV-difference spectroscopy to compare the generation of bilirubin photoproducts by these two light sources, we found enhanced photooxidation of bilirubin with the standard phototherapy unit, while the narrow spectrum unit proved more effective in bilirubin photoisomerization. These results demonstrate the feasibility of developing a phototherapy unit devoid of wavelengths with a potential for long-term genetic sequellae yet effective in bilirubin isomerization. Previous studies from our laboratory demonstrating the intracellular DNA-modifying activity of phototherapy with and without physiologic photosensitizing agents (e.g. vitamins, amino acids) have generated concern since many carcinogens and/or teratogens derive their activity from a similar ability to modify DNA. The present study extends these observations and characterizes the DNA-modifying activity of light-activated riboflavin, a coenzyme ubiquitous to living cells. More specifically, we have demonstrated that among the four naturally occurring deoxyribonucleotides, light-activated riboflavin induces a photochemical change only in deoxyguanosine. Utilizing scavengers and promoters of singlet oxygen (loz) we have determined that this reaction, although oxygen dependent, does not involve '02. In addition, experiments with purified DNA have identified a second, oxygenindependent, photochemical reaction which results in the formation of a covalent adduct between riboflavin and the biopolymer. Moreover, when synthetic copolymers [poly (dAadT); poly (dG0dC)1 are substituted for DNA, covalent binding is observed only with the poly (dA0dT). Therefore, this latter photochemical reaction is independent of deoxyguanosine. The relevance of these two distinct in vitro photochemical reactions to the jaundiced infant receiving phototherapy is under investigation. Our results suggest that phototherapy is a complex process with an inherent potential for serious long-term sequellae. The somatomedins (SM) are a group of peptide hormones which are believed to mediate at least some of growth hormone's anabolic effects. While the role of SM in postnatal growth is well established, its function in prenatal and early postnatal growth is not clear and studies on SM levels in the neonatal period have given conflicting results. Part of the confusion is due to the fact that the assays employed are relatively nonspecific for the different SMs. We have used a highly specific immunoassay to measure SM-C levels in 18 healthy full term neonates (birth weight 2750-3825 gm). SM-C was measured on cord blood (CB) and on samples obtained on days 1,2,3,4,5 and 14. Relative to normal adult serum (1 plml) the CB levels were low (0.27 + .21) and fell to almost undetectable levels within the first day (C0.1).
SM-C levels remained low through day 4 but began to rise on the 5th day (.I9 5 .09). By day 14 the levels were above those seen in cord serum (0.47 2 .28). The low SM-C levels observed in early postnatal life, a period when growth hormone levels are elevated, suggests a relative insensitivity of the neonate to the somatogenic effects of growth hormone.
